olainfarm_Herpelans

HERPELĀNS®

Product INN: Aciclovirum

Deva: 200 mg tablets

Product ATC Code: J05AB01

Product Description

Treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes.
Prevention of recurrent herpes simplex infections in immunocompetent patients.
Prophylaxis of herpes simplex infections in immunocompromised patients (bone marrow transplantation, advanced HIV infection, etc).
Treatment of varicella (chickenpox) and herpes zoster (shingles) infections.

Product Mechanism of Action

Aciclovir is a synthetic analogue of purine nucleoside deoxyguanidine derived from guanine, normal component DNA. Aciclovir is active against herpes simplex virus (HSV) types I( HSV-1) and II (HSV-2), varicella zoster virus (VZV) and some other viruses including Epstein–Barr virus (EBV) and cytomegalovirus (CMV).
Aciclovir is phosphorylated after entry into herpes virus infected cells to the active compound aciclovir triphosphate. The first step in this process is dependent on the presence of the HSV-coded thymidine kinase. The similarity of the structures of aciclovir triphosphate and deoxyguanidine allows aciclovir triphosphate to interact with the virus enzymes in the infected cell preventing further viral DNA synthesis, which leads to the interruption of the multiplication of virus. The viral DNA synthesis inhibitory activity of aciclovir is highly selective without affecting normal cellular processes.
Aciclovir prevents the formation of new rash elements; reduces the possibility of cutaneous dissemination and visceral complications; accelerates the formation of crusts; reduces pain in the acute phase of herpes zoster infection, duration and severity of postherpetic neuralgia.
The medicine also shows immunostimulating activity.
Prolonged or repeated courses of aciclovir in severely immune-compromised individuals may result in the selection of virus strains with reduced sensitivity, which may not respond to continued aciclovir therapy.

Dosage

Treatment with aciclovir should begin as early as possible after the start of an infection (early symptoms are burning and tingling sensation); for recurrent episodes this should preferably be during the prodromal period. Aciclovir Olainfarm 200 mg tablets are for oral administration. It is recommended to take the medicine after meals with a glass of water.

Treatment and prophylaxis of Herpes simplex virus infections.

Adult:
- Herpes simplex infections of the skin and mucous membranes in immunocompetent patients: 200 mg 5 times per day, for 5 days.
- Herpes simplex infections of the skin and mucous membranes in immunocompromised patients or in patients with impaired absorption from the gut: 400 mg 5 times a day, for 5 days.
- Prevention of recurrent Herpes simplex infections in immunocompetent patients: 200 mg 4 times per day, 400 mg 2 times a day or 200 mg 2-3 times a day. The duration of prophylactic administration is determined by the duration of the period at risk. Therapy should be interrupted periodically at intervals of 6 to 12 months.
- Prophylaxis of Herpes simplex infections in immunocompromised patients: 200 mg 4 times per day.
- Prophylaxis of Herpes simplex infections in severely immunocompromised patients or in patients with impaired absorption from the gut: 400 mg 4 times per day. The duration of prophylactic administration is determined by the duration of the period at risk.

Children:
- Under 2 years: half the adult dose;
- 2 years and over: adult dosages.

Treatment of varicella (chickenpox) and herpes zoster (shingles) infections.

Adults:
varicella and herpes zoster infections: 800 mg 5 times per day, duration of 7-10 days.

Children:
varicella (chickenpox) infection: 20 mg/kg (maximum dose - 800 mg) 4 times a day, for 5 days
or
- under 2 years: 200 mg 4 times per day for 5 days;
- 2 to 5 years: 400 mg 4 times per day for 5 days;
- 6 years and over: 800 mg 4 times per day for 5 days.
Not recommended for children with mild form of chickenpox.

Elderly:
In elderly patients the dosage should be reduced accordingly taking into consideration the possibility of renal impairment. Adequate hydration of elderly patients taking high oral doses of aciclovir should be maintained.

Renal impairment:
In the management of herpes simplex infections in patients with mild impairment of renal function, the recommended doses do not lead to accumulation of aciclovir in the organism.
Dose reduction is required in patients with moderate to severe renal impairment.
For patients with moderate renal impairment (creatinine clearance 10 – 25 mL/min) in case of herpes zoster infection 800 mg 3 times a day at a dosing interval of 6 – 8 hours is recommended.
In the management of herpes simplex infections in patients with severe renal impairment (creatinine clearance less than 10 ml/min) an adjustment of dose to 200 mg twice daily is recommended; in case of herpes zoster - 800 mg twice daily at a dosing interval of 12 hours.

Attachments

Before use, carefully read the instructions. Consult your doctor or pharmacist about the use of medicines.
Medicines unreasonable use is harmful to health.